```
Trying 3106016892...Open

Welcome to STN International!  Enter x:x
LOGINID:ssspta1644pnh
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Sep 17   IMSworld Pharmaceutical Company Directory name change
                   to PHARMASEARCH
 NEWS  3  Oct 09   Korean abstracts now included in Derwent World Patents
                   Index
 NEWS  4  Oct 09   Number of Derwent World Patents Index updates increased
 NEWS  5  Oct 15   Calculated properties now in the REGISTRY/ZREGISTRY File
 NEWS  6  Oct 22   Over 1 million reactions added to CASREACT
 NEWS  7  Oct 22   DGENE GETSIM has been improved
 NEWS  8  Oct 29   AAASD no longer available
 NEWS  9  Nov 19   New Search Capabilities  USPATFULL and USPAT2
 NEWS 10  Nov 19   TOXCENTER(SM) - new toxicology file now available on STN
 NEWS 11  Nov 29   COPPERLIT now available on STN
 NEWS 12  Nov 29   DWPI revisions to NTIS and US Provisional Numbers
 NEWS 13  Nov 30   Files VETU and VETB to have open access
 NEWS 14  Dec 10   WPINDEX/WPIDS/WPIX New and Revised Manual Codes for 2002
 NEWS 15  Dec 10   DGENE BLAST Homology Search
 NEWS 16  Dec 17   WELDASEARCH now available on STN
 NEWS 17  Dec 17   STANDARDS now available on STN
 NEWS 18  Dec 17   New fields for DPCI
 NEWS 19  Dec 19   CAS Roles modified
 NEWS 20  Dec 19   1907-1946 data and page images added to CA and CAplus

 NEWS EXPRESS   August 15 CURRENT WINDOWS VERSION IS V6.0c,
                CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP),
                AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001
 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS INTER     General Internet Information
 NEWS LOGIN     Welcome Banner and News Items
 NEWS PHONE     Direct Dial and Telecommunication Network Access to STN
 NEWS WWW       CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *


FILE 'HOME' ENTERED AT 09:47:01 ON 23 JAN 2002
```

=> file medline embase biosis scisearch caplus

COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 0.15 | 0.15

FILE 'MEDLINE' ENTERED AT 09:47:16 ON 23 JAN 2002

FILE 'EMBASE' ENTERED AT 09:47:16 ON 23 JAN 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 09:47:16 ON 23 JAN 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'SCISEARCH' ENTERED AT 09:47:16 ON 23 JAN 2002
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'CAPLUS' ENTERED AT 09:47:16 ON 23 JAN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s vaccine

L1 335209 VACCINE

=> s l1 and CETP

L2 22 L1 AND CETP

=> dup remove l2

PROCESSING COMPLETED FOR L2
L3 15 DUP REMOVE L2 (7 DUPLICATES REMOVED)

=> d l3 1-15 cbib abs

L3 ANSWER 1 OF 15 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE 1
2001:517733 Document No.: PREV200100517733. Plasmid-based **vaccine** for treating atherosclerosis. Thomas, Lawrence J. (1). (1) Easton, MA USA.
ASSIGNEE: AVANT Immunotherapeutics, Inc.. Patent Info.: US 6284533 September 04, 2001. Official Gazette of the United States Patent and Trademark Office Patents, (Sep. 4, 2001) Vol. 1250, No. 1, pp. No Pagination. e-file. ISSN: 0098-1133. Language: English.
AB A plasmid-based **vaccine** is provided herein based on the combination of DNA segments coding for one or more B cell epitopes of cholesteryl ester transfer protein (**CETP**) and one or more broad range helper T cell epitopes. Administration of the plasmids as a **vaccine** to a vertebrate subject provides an immune response to the subject's endogenous **CETP** and modulation of **CETP** activity, leading to prevention or reversal of various manifestations of heart disease. The **vaccines** provide an advantageous strategy for the prevention or treatment of atherosclerosis.

L3 ANSWER 2 OF 15 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE 2
2001:298985 Document No.: PREV200100298985. An extended toxicologic evaluation of an immunoneutralizing **vaccine** to produce anti-**CETP** antibodies for the prevention/treatment of atherosclerosis. Thomas, Lawrence J. (1); Picard, Michele D. (1); Miller, David P. (1); Emmett,

Constance D. (1); Scesney, Susanne M. (1); Pisano, Milissa L. (1); Adari, Hedy (1); Hammond, Russell A. (1); Marsh, Henry C. (1); Rittershaus, Charles W. (1); Pettey, Carolyn L. (1). (1) AVANT Immunotherapeutics, 119 Fourth Ave., Needham, MA, 02494 USA. FASEB Journal, (March 7, 2001) Vol. 15, No. 4, pp. A566. print. Meeting Info.: Annual Meeting of the Federation of American Societies for Experimental Biology on Experimental Biology 2001 Orlando, Florida, USA March 31-April 04, 2001 ISSN: 0892-6638. Language: English. Summary Language: English.

AB A toxicology study was conducted with an immunoneutralizing **vaccine** designed to elicit antibodies that would bind to and block the function of cholesteryl ester transfer protein (**CETP**), in order to prevent atherosclerosis. The **vaccine** consisted of a dimer of a 31 a.a. synthetic chimeric peptide containing an N-terminal cysteine, a T cell epitope (residues 830-843 of tetanus toxin), and a B cell epitope (residues 461-476 of human **CETP**), formulated with an alum adjuvant. In this study NZW rabbits were immunized with either 0 mg (4 males and 4 females), 0.1 mg (2 males and 2 females), 0.25 mg (4 males and 4 females) or 1.0 mg (4 males and 4 females) of the **vaccine** on days 1, 29 and 57. On day 197 (at a relative antibody minimum) half of the animals from groups 1, 3 and 4 were sacrificed. The remaining animals were reboosted and euthanized on day 211, at an expected antibody maximum. Blood samples were taken periodically throughout the study and were assessed for hematology, clinical chemistry, and antibody titers. All rabbits in the non-control groups developed anti-rabbit **CETP** antibody titers, thus validating the immunogenicity of the **vaccine**. In all other measurements the vaccinated groups were indistinguishable from the control group. All animals were monitored for clinical abnormalities throughout the study, and at necropsy, gross pathology was assessed, selected organs were weighed, and samples of 44 tissues were taken for histopathology. By all the above parameters, no significant test article-related pathology was observed. This study demonstrated the administration of this **CETP** immunoneutralizing **vaccine** produced specific self-reactive antibody titers but no detectable test article-related pathology.

L3 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2002 ACS

2002:4125 An immunotherapeutic approach for the treatment of low plasma HDL-Cholesterol. Ryan, Una S.; Rittershaus, Charles W. (AVANT Immunotherapeutics, Inc., Needham, MA, 02494-2725, USA). NATO Science Series, Series I: Life and Behavioural Sciences, 330(Vascular Endothelium), 26-33 (English) 2001. CODEN: NSSSC9. ISSN: 1566-7693. Publisher: IOS Press.

AB One determinant of plasma HDL-Cholesterol concn. is cholesteryl ester transfer protein (**CETP**) activity. Inhibition of **CETP** activity increases plasma HDL-C, thus providing a potential therapeutic target for the treatment of atherosclerosis. Using a **vaccine** approach, we immunized New Zealand White rabbits with a peptide contg. a region of **CETP** known to be required for neutral lipid transfer function. **CETP**-vaccinated rabbits had significantly reduced plasma **CETP** activity and an altered lipoprotein profile compared with control rabbits. In a cholesterol-fed rabbit model of atherosclerosis, the fraction of plasma cholesterol in HDL was 42% higher, and the fraction of plasma cholesterol in LDL was 24% lower in the **CETP**-vaccinated group compared with the control-vaccinated group. Moreover, the percentage of the aorta surface exhibiting atherosclerotic lesion was 39.6% smaller in the **CETP**-vaccinated rabbits compared with controls. The data reported here demonstrate that **CETP** activity can be reduced in vivo by vaccination with a peptide derived from **CETP**, and support the concept that inhibition of **CETP** activity in vivo can be anti-atherogenic. Currently, this **vaccine** is in clin. trials.

L3 ANSWER 4 OF 15 MEDLINE DUPLICATE 3
2000482102 Document Number: 20436374. PubMed ID: 10978256.
Vaccine-induced antibodies inhibit **CETP** activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis.
Rittershaus C W; Miller D P; Thomas L J; Picard M D; Honan C M; Emmett C D; Pettey C L; Adari H; Hammond R A; Beattie D T; Callow A D; Marsh H C; Ryan U S. (AVANT Immunotherapeutics, Inc, Needham, MA 02494, USA.. crittershaus@avantimmune.com) . ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR
BIOLOGY, (2000 Sep) 20 (9) 2106-12. Journal code: B89; 9505803. ISSN: 1524-4636. Pub. country: United States. Language: English.
AB Using a **vaccine** approach, we immunized New Zealand White rabbits with a peptide containing a region of cholesteryl ester transfer protein (
CETP) known to be required for neutral lipid transfer function. These rabbits had significantly reduced plasma **CETP** activity and an altered lipoprotein profile. In a cholesterol-fed rabbit model of atherosclerosis, the fraction of plasma cholesterol in HDL was 42% higher and the fraction of plasma cholesterol in LDL was 24% lower in the **CETP**-vaccinated group than in the control-vaccinated group. Moreover, the percentage of the aorta surface exhibiting atherosclerotic lesion was 39.6% smaller in the **CETP**-vaccinated rabbits than in controls. The data reported here demonstrate that **CETP** activity can be reduced in vivo by vaccination with a peptide derived from **CETP** and support the concept that inhibition of **CETP** activity in vivo can be antiatherogenic. In addition, these studies suggest that vaccination against a self-antigen is a viable therapeutic strategy for disease management.

L3 ANSWER 5 OF 15 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
2000421271 EMBASE Genetic polymorphisms and activity of cholesterol ester transfer protein (**CETP**): Should we be measuring them?. Ordovas J.M.. J.M. Ordovas, Lipid Metabolism Laboratory, Jean Mayer USDA Hum. Nutr. Res. Ctr., Tufts University, Boston, MA, United States. Ordovas@hnrc.tufts.edu. Clinical Chemistry and Laboratory Medicine 38/10 (945-949) 2000.
Refs: 51.
ISSN: 1434-6621. CODEN: CCLMFW. Pub. Country: Germany. Language: English. Summary Language: English.
AB Cholesteryl ester transfer protein (**CETP**) is a glycoprotein that mediates the transfer of cholesteryl ester from high density lipoproteins (HDL) to triglyceride-rich lipoproteins in exchange for triglycerides. Several approaches are currently being used in research
laboratories to measure its activity and/or mass. However, these assays are not standardized and it is not possible to compare data from different
laboratories. Also, we lack enough information to assess the value of this
variable as a coronary heart disease (CHD) predictor. Several genetic variants at **CETP** locus have been identified and they have been generally associated with increased HDL- cholesterol concentrations. However, there is no consensus about the association of this **CETP** -related increase in HDL-cholesterol and protection against CHD. Nevertheless, the most recent evidence from the common **CETP** -Taql-B polymorphism shows that the lower **CETP** activity associated with the presence of this polymorphism decreases CHD risk in men. Based on this and previous evidence, there has been an interest in the development of **CETP** inhibitors as a tool to increase HDL-cholesterol, thus reducing CHD risk. However, it should be noted that the evidence about the cardioprotective role of these drugs is not yet available.

L3 ANSWER 6 OF 15 SCISEARCH COPYRIGHT 2002 ISI (R)
2000:559012 The Genuine Article (R) Number: 313NH. Toxicologic evaluation of an immunoneutralizing **vaccine** to produce anti-**CETP** antibodies for the prevention/treatment of atherosclerosis.. Thomas L J (Reprint); Picard M D; Miller D P; Emmett C D; Scesney S M; Adari H; Hammond R A; Levin J L; Ryan U S; Marsh H C; Pettey C L; Rittershaus C W.
AVANT IMMUNOTHERAPEUT INC, NEEDHAM, MA 02494. FASEB JOURNAL (11 MAY 2000)
Vol. 14, No. 8, pp. 262-262. Publisher: FEDERATION AMER SOC EXP BIOL. 9650
ROCKVILLE PIKE, BETHESDA, MD 20814-3998. ISSN: 0892-6638. Pub. country: USA. Language: English.

L3 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2002 ACS
1999:282118 Document No. 130:310673 Xenogeneic cholesteryl ester transfer protein (**CETP**) for modulation of **CETP** activity in treatment of atherosclerosis. Rittershaus, Charles W.; Thomas, Lawrence J. (Avant Immunotherapeutics, Inc., USA). PCT Int. Appl. WO 9920302 A1 19990429, 62 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1998-US22145 19981020. PRIORITY: US 1997-954643 19971020.
AB Methods for modulating cholesteryl ester transfer protein (**CETP**) activity and the plasma levels of lipoproteins involved in heart disease involve administration of a non-endogenous **CETP** or a plasmid-based **vaccine** for expression of such non-endogenous **CETP** to elicit prodn. in a mammal of antibodies that recognize (bind to) the mammal's native (endogenous) **CETP**.

L3 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2002 ACS
1999:223038 Document No. 130:250711 Vector **vaccines** against cholesterol ester transfer protein for the treatment of atherosclerosis. Needleman, Philip; Glenn, Kevin (Monsanto Company, USA). PCT Int. Appl. WO 9915655 A1 19990401, 99 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1998-US19366 19980917. PRIORITY: US 1997-934367 19970919.
AB Expression vectors for manuf. of antigenic fragments of cholesteryl ester transfer protein (**CETP**) that can be used to inactivate the protein are described. The protein plays a key role in the transfer of cholesterol from HDL to LDL and VLDL and inhibition of **CETP** synthesis can be used to prevent LDL and VLDL formation in the prophylaxis of atherosclerosis. Immunogens, inocula, DNA segments, and recombinant DNA mol. vectors useful for carrying out the invention are also disclosed.
The use of antigenic fragments of rabbit **CETP** to raise autoantibodies in rabbits is demonstrated. Antibodies to three such peptides cross-reacted with human **CETP**. Rabbits vaccinated with these antigens showed a .apprx.10% increase in serum HDL. Antigens were manufd. as fusion proteins with hepatitis B core antigens in Escherichia coli, in a baculovirus system, and in mammalian cell culture.

L3 ANSWER 9 OF 15 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE 4
1999:282999 Document No.: PREV199900282999. A **vaccine** to produce anti-cholesteryl ester transfer protein (**CETP**) antibodies for the prevention/treatment of atherosclerosis. Thomas, L. J. (1); Picard, M.
D. (1); Miller, D. P. (1); Honan, C. M. (1); Adari, H. (1); Emmett, C. D. (1); Marsh, H. C. (1); Ryan, U. S. (1); Pettey, C. L. (1); Rittershaus, C.
W. (1). (1) Avant Immunotherapeutics, Inc., Needham, MA, 02494 USA. FASEB Journal, (March 15, 1999) Vol. 13, No. 5 PART 2, pp. A693. Meeting Info.: Annual Meeting of the Professional Research Scientists on Experimental Biology 99 Washington, D.C., USA April 17-21, 1999 Federation of American Societies for Experimental Biology. ISSN: 0892-6638. Language: English.

L3 ANSWER 10 OF 15 SCISEARCH COPYRIGHT 2002 ISI (R)
1998:762763 The Genuine Article (R) Number: 121HC. Use of xenogeneic cholesteryl ester transfer protein (**CETP**) in a plasmid-based **vaccine** to produce anti-**CETP** autoantibodies for the prevention/treatment of atherosclerosis.. Thomas L J (Reprint); Adari H; Picard M D; Honan C M; Miller D P; Rittershaus C W; Pettey C L. T CELL SCI
INC, NEEDHAM, MA. FASEB JOURNAL (17 MAR 1998) Vol. 12, No. 4, Part 1, Supp. [S], pp. 1805-1805. Publisher: FEDERATION AMER SOC EXP BIOL. 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998. ISSN: 0892-6638. Pub. country: USA. Language: English.

L3 ANSWER 11 OF 15 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
1998:200178 Document No.: PREV199800200178. Use of xenogeneic cholesteryl ester transfer protein (**CETP**) in a plasmid-based **vaccine** to produce anti-**CETP** autoantibodies for the prevention/treatment of atherosclerosis. Thomas, L. J.; Adari, H.; Picard, M. D.; Honan, C. M.;
Miller, D. P.; Rittershaus, C. W.; Pettey, C. L.. T Cell Sciences Inc., Needham, MA USA. FASEB Journal, (March 17, 1998) Vol. 12, No. 4, pp. A310.
Meeting Info.: Annual Meeting of the Professional Research Scientists on Experimental Biology 98, Part 1 San Francisco, California, USA April 18-22, 1998 Federation of American Societies for Experimental Biology. ISSN: 0892-6638. Language: English.

L3 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2002 ACS
1997:740308 Document No. 128:10315 Plasmid-based **vaccine** for treating atherosclerosis. Thomas, Lawrence J. (T Cell Sciences, Inc., USA; Thomas, Lawrence J.). PCT Int. Appl. WO 9741227 A1 19971106, 66 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ,
DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1997-US7294 19970501. PRIORITY: US 1996-640713 19960501; US 1997-802967 19970221.
AB A plasmid-based **vaccine** is provided that is based on the combination of DNA segments coding for one or more B cell epitopes of **CETP** and one or more broad range helper T cell epitopes. Administration of the plasmids as a **vaccine** to a vertebrate subject provides an immune response to the subject's endogenous **CETP** and modulation of **CETP** activity, leading to prevention or reversal of various manifestations of heart disease. The **vaccines** provide an advantageous strategy for the prevention or treatment of atherosclerosis.

L3 ANSWER 13 OF 15 SCISEARCH COPYRIGHT 2002 ISI (R)
97:166073 The Genuine Article (R) Number: WH142. A plasmid-based **vaccine** to elicit autoantibodies to cholesteryl ester transfer protein (**CETP**) for the prevention/treatment of atherosclerosis.. Thomas L J (Reprint); Picard M D; Stewart S E; WAite B C D; Lin A Y; Rittershaus C W; Pettey C L. T CELL SCI INC, NEEDHAM, MA. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (JAN 1997) Vol. 99, No. 1, Part 2, Supp. [S], pp. 754-754. Publisher: MOSBY-YEAR BOOK INC. 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318. ISSN: 0091-6749. Pub. country: USA
. Language: English.

L3 ANSWER 14 OF 15 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
1997:144273 Document No.: PREV199799443476. A plasmid-based **vaccine** to elicit autoantibodies to cholesteryl ester transfer protein (**CETP**) for the prevention/treatment of atherosclerosis. Thomas, L. J.; Picard, M. D.; Stewart, S. E.; Waite, B. C. D.; Lin, A. Y.; Rittershaus, C. W.; Pettey, C. L.. T Cell Sci. Inc., Needham, MA USA. Journal of Allergy and Clinical Immunology, (1997) Vol. 99, No. 1 PART 2, pp. S187. Meeting Info.: Joint Meeting of the American Academy of Allergy,
Asthma and Immunology, the American Association of Immunologists and the Clinical Immunology Society San Francisco, California, USA February 21-26,
1997 ISSN: 0091-6749. Language: English.

L3 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2002 ACS
1997:12606 Document No. 126:46315 Modulation of cholesteryl ester transfer protein (**CETP**) activity. Rittershaus, Charles W.; Thomas, Lawrence J. (T Cell Sciences, Inc., USA; Rittershaus, Charles W.; Thomas, Lawrence J.). PCT Int. Appl. WO 9634888 A1 19961107, 81 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1996-US6147 19960501. PRIORITY: US 1995-432483 19950501.
AB This invention relates to peptides comprising a helper T cell epitope portion and a B cell epitope portion for eliciting an immune response against endogenous cholesteryl ester transfer protein (**CETP**) activity, to prevent or treat cardiovascular disease, such as atherosclerosis. The T helper T cell epitope may be derived from an antigenic peptide selected from the group consisting tetanus toxoid, diphtheria toxoid, pertussis **vaccine**, Bacile Calmette-Guerin, polio **vaccine**, measles **vaccine**, mumps **vaccine** , rubella **vaccine**, purified protein deriv. of tuberculin, keyhole limpet hemocyanin, hsp70 and combination thereof.

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	42.06	42.21
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.10	-3.10

STN INTERNATIONAL LOGOFF AT 09:48:13 ON 23 JAN 2002